Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Endometrial Cancer
  •  Chemotherapy and Radiotherapy
  •  Radiation Oncology
  •  Carcinomas
  •  Hematology
  •  Palliative Care
  •  Head and Neck Oncology
  •  Targeted Therapy

Abstract

Citation: Clin Oncol. 2016;1(1):1075.DOI: 10.25107/2474-1663.1075

Renal Cell Carcinoma with Parieto-Occipital Bone Metastasis

Mittal V, Rupala KK, Ahmad J and Suryavanshi M

Department of Urology, Kidney Transplant and Robotics, India

*Correspondance to: Varun Mittal 

 PDF  Full Text Clinical Image | Open Access

Abstract:

One third patients with renal cell carcinoma (RCC) have metastatic disease at presentation. Eight to 15% patients present with metastases in head and neck region. Skull bone metastasis is a very rare presentation. Herein we report a case of 56 year male RCC with parieto-occipital bone metastasis. He underwent radiotherapy for skull lesion and cytoreductive nephrectomy for right renal mass. Metastatic RCC is a diagnostic dilemma especially when there is no clue in clinical presentation. An unusual vascular osteolytic lesion in head and neck in middle-aged person should be dealt with a high index of suspicion for RCC.

Keywords:

Cite the Article:

Mittal V, Rupala KK, Ahmad J, Suryavanshi M. Renal Cell Carcinoma with Parieto-Occipital Bone Metastasis. Clin Oncol. 2016; 1: 1075.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Analysis of CMTM6 and CMTM4 Expression as Potential Regulators of the PD-L1 Protein and its Association with Prognosis in Gliomas
 Abstract  PDF  Full Text
Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
View More...